Biopharma Split on Treasury's China Rule: Contract Manufacturing Exemption Sparks Debate

The U.S. Treasury Department's proposed rule restricting certain outbound investments to China has exposed a rift within the biopharma industry, with disagreement centered on an exemption for contract manufacturing deals. The rule, which implements an executive order targeting national security threats from China in semiconductors, quantum computing, and artificial intelligence, may also capture some biotechnology transactions. While the biotech sector is not explicitly named, the broad definition of 'covered transactions' has raised concerns among companies and investors about potential unintended consequences for drug development and manufacturing partnerships. Key players, including large pharmaceutical companies and smaller biotechs, are split: some argue the exemption is necessary to maintain global supply chains and accelerate drug production, while others warn it could create loopholes that undermine the rule's intent. The Treasury is accepting public comments, and the final rule could significantly affect U.S.-China biopharma collaboration, with billions in investment at stake. The outcome will shape how American drugmakers navigate an increasingly tense geopolitical landscape, balancing innovation with security.